Aurobindo Pharma's subsidiary to acquire product under development from Advent Pharmaceuticals

The Board of Aurobindo Pharma at its meeting held on 12 November 2018 has transacted the following -

The company's subsidiary - Aurobindo Pharma USA Inc., USA, has entered into an agreement to acquire a product under development and related assets from 'Advent Pharmaceuticals, Australia, through AuroScience, Melbourne, a 100% subsidiary of Aurobindo Pharma USA Inc., USA. The transaction is expected to close in January 2019. The cost of acquisition is USD 12.5 million.

Powered by Capital Market - Live News